ONA, OTCQBNANF) CEO David Regan talked with Proactive about the company's first-in-human clinical trial using its THT therapy for late-stage melanoma patients. Regan explained that Sona has dosed the first patient in Santiago, Chile, marking a significant step from preclinical work into clinical testing. 